/
© 2026 RiffOn. All rights reserved.

Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

  1. Research To Practice | Oncology Videos
  2. Metastatic Triple-Negative Breast Cancer — 5-Minute Journal Club Activity 1 with Dr David W Cescon
Metastatic Triple-Negative Breast Cancer — 5-Minute Journal Club Activity 1 with Dr David W Cescon

Metastatic Triple-Negative Breast Cancer — 5-Minute Journal Club Activity 1 with Dr David W Cescon

Research To Practice | Oncology Videos · Sep 21, 2026

First-line mTNBC evolves with Trop-2 ADCs. Dr. Cescon compares sacituzumab & datopotamab trials, highlighting efficacy vs. distinct toxicities.

Geographic Survival Disparities in TROPION-Breast02 Caused by Access to Care, Not Efficacy

The apparent lack of survival benefit for datopotamab in North American patients is likely an artifact. Better access to other effective antibody-drug conjugates after progression in the control arm diluted the survival advantage, highlighting how regional care standards can confound trial outcomes.

Metastatic Triple-Negative Breast Cancer — 5-Minute Journal Club Activity 1 with Dr David W Cescon thumbnail

Metastatic Triple-Negative Breast Cancer — 5-Minute Journal Club Activity 1 with Dr David W Cescon

Research To Practice | Oncology Videos·2 months ago

Pivotal ADC Trials Lack Data for Patients Relapsing After Standard Neoadjuvant Immunotherapy

Current first-line ADC trials for metastatic TNBC largely excluded patients who relapsed after receiving the KEYNOTE-522 neoadjuvant chemo-immunotherapy regimen. This timing mismatch creates a critical evidence gap for an increasingly common clinical scenario, forcing clinicians to rely on real-world data.

Metastatic Triple-Negative Breast Cancer — 5-Minute Journal Club Activity 1 with Dr David W Cescon thumbnail

Metastatic Triple-Negative Breast Cancer — 5-Minute Journal Club Activity 1 with Dr David W Cescon

Research To Practice | Oncology Videos·2 months ago

ASCENT-03's Crossover Design Muddled Sacituzumab Govitecan's Survival Data

The ASCENT-03 trial allowed control arm patients to receive sacituzumab govitecan upon progression. This ethical choice complicates overall survival interpretation, as many control patients ultimately got the active drug, making direct comparison with non-crossover trials like TROPION-Breast02 difficult.

Metastatic Triple-Negative Breast Cancer — 5-Minute Journal Club Activity 1 with Dr David W Cescon thumbnail

Metastatic Triple-Negative Breast Cancer — 5-Minute Journal Club Activity 1 with Dr David W Cescon

Research To Practice | Oncology Videos·2 months ago

G-CSF Use With Sacituzumab Is Driven by Infusion Center Logistics, Not Just Safety

Prophylactic G-CSF is used with sacituzumab govitecan not only to prevent febrile neutropenia but for practical reasons. It helps ensure patients' blood counts recover for their Day 8 dose, preventing treatment delays and simplifying scheduling for busy infusion centers.

Metastatic Triple-Negative Breast Cancer — 5-Minute Journal Club Activity 1 with Dr David W Cescon thumbnail

Metastatic Triple-Negative Breast Cancer — 5-Minute Journal Club Activity 1 with Dr David W Cescon

Research To Practice | Oncology Videos·2 months ago

TROPION-Breast02 Trial Provides Key Data for Rapidly Relapsing TNBC Patients

Unlike ASCENT-03, which required a six-month treatment-free interval, the TROPION-Breast02 trial for datopotamab deruxtecan included patients with immediate relapse after prior therapy. This provides crucial evidence for treating a high-need population with a very poor prognosis, a group often excluded from pivotal trials.

Metastatic Triple-Negative Breast Cancer — 5-Minute Journal Club Activity 1 with Dr David W Cescon thumbnail

Metastatic Triple-Negative Breast Cancer — 5-Minute Journal Club Activity 1 with Dr David W Cescon

Research To Practice | Oncology Videos·2 months ago

Trop-2 Expression Is Not a Useful Biomarker for Choosing ADCs Over Chemotherapy

Trop-2 antibody-drug conjugates (ADCs) outperform chemotherapy in metastatic triple-negative breast cancer regardless of the patient's Trop-2 expression level. While higher expression correlates with better response, the ADCs are superior even in low-expressing tumors, making it an ineffective selection tool versus chemo.

Metastatic Triple-Negative Breast Cancer — 5-Minute Journal Club Activity 1 with Dr David W Cescon thumbnail

Metastatic Triple-Negative Breast Cancer — 5-Minute Journal Club Activity 1 with Dr David W Cescon

Research To Practice | Oncology Videos·2 months ago